Notification report

Full notification file

General information

Notification Number

Member State to which the notification was sent

Date of acknowledgement from the Member State Competent Authority

Title of the Project
Phase I/II trial investigating an immunostimulatory oncolytic adenovirus for cancer

Proposed period of release:
01/10/2017 to 30/11/2020

Name of the Institute(s) or Company(ies)
Lokon Pharma AB, ;

3. Is the same GMO release planned elsewhere in the Community?

Has the same GMO been notified elsewhere by the same notifier?

GMO characterization

GMO is a:
DNA Virus

Identity of the GMO:
LOAd703 is an adenovirus group C serotype 5 with changed fiber to serotype 35 in L5. It has
deletions in E1 and E3 regions: E1Adelta24, E3deltagp19K and E3delta6.7K. Ahead of E1A it has 8
E2F sites (4 palindromes) and one Sp-1 site. A transgene cassette is inserted after L5 including a CMV promoter, human full length 4-1BBL and an extracellular and intracellular domain of human CD40L fused to an isoleucine zipper domain (TMZ-CD40L) (Eriksson et al, Clin Cancer Res, 2017, Epub ahead of print).

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
Ad5Mastadenovirushuman adenovirussubgroup Cserotype 5-

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known